Sandoz Paroxetine 20 mg tablets

Paroxetine Sandoz is a generic pharmaceutical product containing paroxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI) used primarily to treat depression and anxiety disorders. The brand traces its historical roots back to 1886, when it was founded in Basel, Switzerland, originally as a chemical and dye manufacturer before pivoting to pharmaceuticals in the late 19th century.

Manufacturing of Sandoz products occurs across a global network of specialized facilities. While the company maintains significant production hubs in Europe—most notably in Austria (Kundl) and Slovenia—it also utilizes manufacturing sites in other regions to serve over 100 markets worldwide. The specific country of origin for a single pack can vary depending on the local market and the batch's production site.

Ownership of the Sandoz brand has undergone significant changes in recent decades. After merging with Ciba-Geigy in 1996 to form Novartis, the Sandoz name was later revitalized as Novartis's dedicated generics division. In October 2023, Sandoz was successfully spun off into a completely independent, publicly traded entity headquartered in Basel, Switzerland. As of 2026, it operates as a standalone global leader in generic and biosimilar medicines, owned by a diverse base of public and institutional shareholders.